Tuesday 7 July 2015, Amsterdam
A new report, now available on ASDReports, calculates that the global dermatological drugs market will reach $24.5bn in 2015 with revenues showing growth to 2025. These revenue forecasts and others appear in the report Dermatological Drugs Market Forecast 2015-2025: Opportunities For Leading Companies.
The market for dermatological drugs presents an opportunity for truly innovative products to make significant impact. This market is relatively fragmented, with a large number of drugs competing for the available market shares. This is true for most of the main disease areas within dermatology. There are many drugs that have lost marketing exclusivity in major markets such as the US and EU and have therefore been subjected to generic drug competition. Despite increased generic drug penetration, the market for dermatological drugs is a growing one with a hive of activities and multiple products in various stages of development. The psoriasis drugs sector, which accounts for a major share of the dermatological drugs market, is currently dominated by biologics in term of revenue. We expect the high price of these drugs coupled with the increase in their usage to help drive growth in the market for dermatological drugs over the coming years.
Moses Akintomide-Akinwamide, a senior pharmaceutical and medical technology market analyst explains: “Over the last two decades, the dermatological drugs market has been driven by both new drugs and reformulations of existing products. This growth is set to continue driven by the global aging population and the expected boom in incidence of dermatological conditions in various regions around the globe. The market has shown itself to possess marked strengths and advantages to facilitate growth. Therefore, we expect the small biotech and specialist pharma companies with innovative technologies to continue to be drawn to this market over the coming decade. Increased demand and funding for new anti-bacterial drugs will also benefit these small innovative companies. This will aid growth within the market for dermatological drugs. Amidst the continuous decline in reimbursement for dermatological drugs, we expect expansion in the market to be particularly dependent on reformulations of existing drugs, providing better drug delivery, new dosing schedules, and targeting more specific patient populations.”
The report provides revenue forecasts to 2025 for the global dermatological drugs market and its leading regional and national markets. It forecast sales in the US, EU5 (Germany, Spain, Italy, UK, and France), India, Japan, China, Brazil, Russia, and Mexico. The report also forecasts sales for individual segments of the dermatological drugs market. These include the psoriasis drugs, dermatitis drugs, acne drugs and skin infection drugs segments of the market. Analysis and forecasts for key marketed products in each of these segments are provided together with profiles, analyses, and forecasts of products in the development pipeline.
Analyses and evaluation of historical revenue and business operations of 6 leading companies within the market are also provided together with evaluation of their future potential. Where possible, the dermatological drug revenue for these companies is also forecasted to 2025. The report also includes analyses of strengths, weaknesses, opportunities, and threats to the market, as well as porter’s five force analyses examining the powers of suppliers and buyers, the threat of substitutes and new entrants, and the rivalry amongst competitors in the market. Transcript of interviews with key opinion leaders in the industry sharing their views on current market trends and the unmet needs in the market are also included in the report.
Publish date : May 2015
Report code : ASDR-207086
Pages : 310